Fitzpatrick, Cella, Harper & Scinto LLP, one of the world’s premier intellectual property law firms, announced today that Donald Heckenberg, Jason Leonard, and Brendan O’Malley have been elected partners of the firm.
“Donald, Jason, and Brendan have each demonstrated a strong commitment to Fitzpatrick and we are excited to welcome them to our partnership,” said Dominick Conde, partner and member of the Management Committee. “We are proud to announce the achievements of these three lawyers who have served the firm and our clients with the highest level of professionalism and service.”
Donald
H. Heckenberg, Jr., Patent Prosecution, Washington, D.C.
Donald
Heckenberg conducts preparation and prosecution of patent applications
in chemical, mechanical, and electrical arts. Mr. Heckenberg also
handles complex proceedings before the U.S. Patent and Trademark Office,
including reexaminations, reissue applications, and post grant
proceedings at the Patent Trial and Appeal Board. In addition, Mr.
Heckenberg’s practice includes patent-related counseling, such as
conducting due diligence investigations, and preparation of opinions on
infringement, validity, and enforceability. He received his J.D. from
American University Washington College of Law, and his B.S. from
Northwestern University.
Jason
A. Leonard, Litigation, New York
Jason Leonard’s
practice focuses on complex pharmaceutical patent litigation. Mr.
Leonard has extensive experience litigating pharmaceutical patents
involving enantiomers, polymorphs, and drug formulations. His litigation
experience includes patents concerning oncology drugs, antifungal
agents, and oral contraceptives. Mr. Leonard is also a co-author of the
United States chapter in The Intellectual Property Review, now in
its fourth edition. Before practicing law, Mr. Leonard worked for six
years as a solid-state and analytical chemist at Pfizer. His work
included development of analytical methods for drug formulations and
synthesis of novel polymorphs and salts of pharmaceutical compounds. Mr.
Leonard is a co-inventor on several solid-state pharmaceutical patents,
including patents for atorvastatin (Lipitor®). He received his J.D. from
Franklin Pierce Law Center (now the University of New Hampshire) and his
B.S. from the University of Connecticut.
Brendan
M. O’Malley, Ph.D., Litigation, New York
Brendan
O’Malley has experience in all aspects of intellectual property law. Dr.
O’Malley represents clients in a broad range of pharmaceutical and
biotechnology cases including litigations at the district court level
through trial and before the Federal Circuit on appeal, as well as in
post-grant proceedings before the USPTO’s Patent Trial and Appeal Board.
Dr. O’Malley has also represented clients in international arbitration
proceedings, and counsels clients on complex IP issues and in connection
with mergers and acquisitions, particularly in the areas of
biotechnology and pharmaceuticals. Dr. O’Malley is a member of the
firm’s Biotechnology, Chemicals, and Pharmaceuticals industry groups. He
received his J.D. from the Benjamin N. Cardozo School of Law, his Ph.D.
from Tufts University School of Medicine, and his B.S. from the
University of Massachusetts.
About Fitzpatrick, Cella, Harper & Scinto LLP:
Fitzpatrick, Cella, Harper & Scinto (www.fitzpatrickcella.com), founded in 1971, is a leading national intellectual property law firm of nearly 150 lawyers with offices in New York, Washington D.C. and Orange County, California that serve a diverse national and international clientele from start-ups to Fortune 500 companies. At Fitzpatrick, intellectual property is not just a practice area – it is the sole focus. The firm’s practice covers the spectrum of intellectual property services, including applying for patent and trademark protection, litigation, appeals, interferences, post-grant challenges (e.g., IPRs), alternative dispute resolution, licensing, opinions, corporate transactions and due diligence.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107006253/en/